Google+

June 6-9, 2016 | San Francisco, CA

Double Helix Sponsor

loading...

Schedule at a glance

Register Now

 

 

BIO Buzz - Official Show Daily, Brought to you by Alexandria

Business Development/Finance

Videos

Jeff Greene, Ernst & Young at the 2015 BIO International Convention
Anthony Raeside, Head of Research, EvaluatePharma at the BIO Buzz Center 2015
Mitch Horowitz, Batelle Technology Partnership Practice at the 2015 BIO International Convention
Tom Zioncheck, Senior Director of Business Development, Genentech at the BIO Buzz Center 2015
Scott Whitaker, President of BIO 2015
William Waddill, Calithera Biosciences at the 2015 BIO International Convention
Joel Marcus, Alexandria Real Estate at the 2015 BIO International Convention
Ron Cohen, Acorda at the 2015 BIO International Convention
Suzanne Ffolkes, Research!America at the 2015 BIO International Convention
David Piacquad, Amgen at the 2015 BIO International Convention
Tim Walbert, CEO, Horizon Pharma, at the BIO Buzz Center 2015
Greg Sturmer President and CEO, Elysium Therapeutics, at the BIO Buzz Center 2015
Andy Gogates, Rutgers Business School at the 2015 BIO International Convention
Maria Thacker, CSBI and Larry Mahan, BIOTechnology Insitute, at the BIO Buzz Center 2015
Bayan Takizawa, Chief Business Officer, ContinuUs, at the BIO Buzz Center 2015

Articles from BioTechNow

Riding the Bull Market: What’s in Store for Biotech Dealmakers in 2015?

Publish Date: 6/18/2015, Created By: BIOtechNOW Editor


In many ways, 2014 was a record year for biopharma dealmaking, with $355 billion in total transactions, including $53 billion in partnering deals, $16.5 billion in venture investments and 133 IPOs. According to the 2015 Campbell Alliance Dealmakers’ Intentions Study, 2015 is shaping up to be the year of historic M&A in the biopharmaceutical sector, driven in part by greater access to capital. The partnering numbers at BIO 2015 further indicate that the appetite for ...

Read More >

The Next Step: How Companies Build Successful Therapeutic Franchises from the Ground Up

Publish Date: 6/18/2015, Created By: BIOtechNOW Editor


Building a new franchise in a therapeutic from scratch poses a host of challenges, from whether to take the risk of entering a new area at all to whether and how to partner strategically with another company. It’s a challenge for both the biggest biopharma companies and emerging biotechs to evaluate how and when to enter new therapeutic areas and to try to ensure that their efforts will not only help patients in need but ...

Read More >

How to Grow a Sustainable Biotech Company? Three Success Stories

Publish Date: 6/18/2015, Created By: Eleena Korban


Katrine Bosley, CEO of Editas Medicine kicked off the session by introducing panelists from three biotech firms with drug candidates in various stages: Arndt Schottelius, CDO of MorphoSys,  Loredana Ablondi, Licensing Manager of Chiesi Farmaceutici SpA (Cheisi) and Andre Hoekema, Senior Vice President of Corporate Development at Galapagos NV. The panelists spoke about the importance of critical alliances which enabled them to grow their companies, and the possibilities that emerged from them. For MorphaSys, this ...

Read More >

Outdated Payments Systems Aren’t Keeping Pace With Medical Innovation

Publish Date: 6/17/2015, Created By: Tracy Cooley


We are experiencing an era of rapid medical progress thanks to the accelerated pace at which new breakthroughs are being uncovered. The compression in time between research and the creation of new treatments is a triumph for patients but a challenge for our outdated healthcare delivery system. Our payment systems were constructed to finance medical costs that increased at predictable rates but are now outdated because of the breakthrough medical advances constantly being made. The ...

Read More >

Business Development and Building the Relationship After BIO

Publish Date: 6/16/2015, Created By: BIOtechNOW Editor


There is a great energy here at BIO, and you can feel it as you walk through the Business Forum and see everyone talking, sharing information, and exchanging business cards.  Nowhere else do you feel that buzz of excitement that comes from sharing innovative ideas and knowing the person you are speaking with feels the same.  But what happens next?  BIO is just the beginning. What happens after BIO is just as important as making ...

Read More >

Pharma R&D Pipeline Value Jumps 18 Percent to $493 Billion

Publish Date: 6/16/2015, Created By: BIOtechNOW Editor


The pharmaceutical industry continues its impressive two-year growth with no signs of slowing down according to new consensus forecast data from the annual state of the industry report, “World Preview 2015, Outlook to 2020” from market intelligence firm, Evaluate. The report, which launched today at the 2015 BIO International Convention, found that worldwide prescription drug sales are expected to grow at 4.8 percent a year until 2020 – growth that is being fueled by the ...

Read More >

Life Science Leader Asks: What Biopharma Trends Should Pharma Execs Be Paying Attention To?

Publish Date: 6/12/2015, Created By: BIOtechNOW Editor


In my last installment of this four-part series interviewing Peter Young, executive-in-residence with A.M. Pappas & Associates, I asked what trends should biopharma execs be paying greater attention to and why. Check out my interview to get insights from Peter on upcoming trends! Peter’s session, Inventing Your Own Hub: Evolving Institutional Models for Translational Medicine, will be taking plan June 16 from 3:30 p.m.-4:45 p.m. in room 105AB. If you missed the earlier segments in this series, here is Part 1, ...

Read More >

Life Science Leader Asks: What Areas Are Often Overlooked by Academics Turned Biotech Entrepreneurs?

Publish Date: 6/11/2015, Created By: BIOtechNOW Editor


In my third installment of a four-part series interviewing Peter Young, executive-in-residence with A.M. Pappas & Associates, he shared missteps made by academics aspiring to become entrepreneurs and also offered up some advice on partnering with VCs. Check out my interview, which will include lessons that won’t be a part of his 2015 BIO International Convention session, Inventing Your Own Hub: Evolving Institutional Models for Translational Medicine, (June 16, 3:30 p.m.-4:45 p.m., room 105AB) Here is Part 1, ...

Read More >

State of the Industry for Emerging Therapeutic Companies

Publish Date: 6/11/2015, Created By: David Thomas, CFA


Emerging therapeutic companies are at their strongest point in a decade. In our new report on investment and deal trends, the BIO Industry Analysis team shows how this segment within the biotech industry has been faring over the last 10 years. The annual aggregate totals show that for almost every funding or deal activity analyzed, 2014 was the peak year of the last decade. A strong public market, a revitalized private funding environment, and a ...

Read More >

Maximize Your Savings Potential During BIO International Convention

Publish Date: 6/10/2015, Created By: Rena'e Love


$161,000,000 That’s how much BIO saved life science companies in aggregate on their 2014 purchases of products and services. More than 2,800 companies nationwide participate in the industry’s largest cost savings program known as BIO Business Solutions®, by taking advantage of the program’s preferential pricing and other benefits. Find out how your company can save money and become a partaker by stopping by the Member Services Pavilion at booth #2001 during the convention. BIO’s Member Services ...

Read More >

Thank you to our 2015 Sponsors

Double Helix Sponsors

Helix Sponsors

Sponsors